Abstract: The present invention relates to methods for controlling and/or treating RNA-replicating viral infections which afflict human beings, animals and/or plants. Specifically, the RNA chain terminating agents, 3'-deoxyribouracil, 3'-deoxyriboguanine and 3'-deoxyribocytosine are useful in treating RNA-replicating viral infections.

Abstract: A method is described for screening retinoid X receptor agonists or antagonists using a retinoid X receptor expressed by a yeast expression system to screen a compound having a retinoid X receptor agonist or antagonist activity. Another screen is described for detecting a compound having retinoid X receptor agonist or antagonist activity by: (1) providing a yeast strain which expresses the retinoic acid receptor and activates a reporter plasmid containing apolipoprotein AI gene site A or a mutated variant thereof; (2) incubating the compound in suitable media and a colorless chromogenic substrate; and (3) examining the media for development of color. Mutated variants of apolipoprotein AI gene site A which respond selectively to the retinoid X receptor or respond to receptors other than RXR.alpha. are also described.

Abstract: A method is described for screening retinoid X receptor agonists or antagonists using a retinoid X receptor expressed by a yeast expression system to screen a compound having a retinoid X receptor agonist or antagonist activity. Another screen is described for detecting a compound having retinoid X receptor agonist or antagonist activity by: (1) providing a yeast strain which expresses the retinoic acid receptor and activates a reporter plasmid containing apolipoprotein AI gene site A or a mutated variant thereof; (2) incubating the compound in suitable media and a colorless chromogenic substrate; and (3) examining the media for development of color. Mutated variants of apolipoprotein AI gene site A which respond selectively to the retinoid X receptor or respond to receptors other than RXR.alpha. are also described.

Abstract: The present invention relates to novel growth hormone-releasing peptides and method for increasing the release of growth hormone levels in mammals, as well as method for increasing milk production in dairy cows and increasing growth rates of animals, such as cattle, sheep, swine, and others. The novel peptides of this invention surprisingly are effective for releasing growth hormone levels in animals by replacing the natural amino acids in positions 1, 2, 3, 8, 9, 10, 12, 21 and 27, as well as derivatizing the N-terminal amino acid residue in human pancreatic islet tumor origin growth hormone-releasing factor.

Abstract: The present invention relates to novel fragments of basic fibroblast growth factor (bFGF). The mitogenic potency of one of these bFGF fragments, identified as HBF-2 is about 25-50 fold less than that of native bFGF but at least 10.sup.3 -10.sup.4 fold more active than that of previously reported synthetic fragments of bFGF. Therefore, the present invention provides the shortest fragment of bFGF that retains substantial biologic activity.

Abstract: The present invention relates to DNA sequences useful in directing low to moderate expression of proteins in E. coli. The sequences are on based on modification of the repressor binding site of the tetA gene of transposon Tn10.

Abstract: The present invention relates to novel chimeric fibroblast growth factors (FGF) wherein the alanine at amino acid 3 and serine 5 of native human recombinant basic fibroblast growth factor are replaced with glutamic acid. The N-terminus sequence of the present chimeric FGFs identify homology with that of human acidic fibroblast growth factor. The mitogenic properties of the native human recombinant basic FGF are exhibited by the present chimeric FGFs, and they are efficiently expressed in E. coli at significantly greater yields that previously reported. Novel variants of this new glu.sup.3,5 basic fibroblast growth factor, such as those in which cysteine 78 and cysteine 96 are replaced, e.g., with serine or other amino acids, to produce stabilized versions of the glu.sup.3,5 basic FGF and eliminate disulfide scrambled forms, are also described.

Abstract: The present invention relates to a method for identifying a TonB inhibitor in a test sample comprising:(a) growing a TonB.sup.+ microorganism in the presence of the test sample and a lethal agent, the activity of which is mediated by TonB;(b) identifying as positive a test sample with which the lethal activity of the agent is not observed;(c) growing on a low-iron medium a TonB.sup.+ microorganism in the presence of the test sample identified as positive in (b);(d) confirming as positive a test sample with which growth inhibition of the microorganism is observed on a low-iron medium.

Abstract: An isolated polypeptide corresponding to the epitope of porcine somatotropin is provided by this invention as well as methods of enhancing the growth of an animal by administering to the animal this polypeptide in compositions.

Abstract: Cytokines are useful for the ability to improve the natural defense system of the involuting mammary gland. In addition to the immunopotentiating activity, cytokines accelerate the normal physiology of involution of the mammary gland and thereby afford further protection against new infections of mammals. The involuting mammary gland is very susceptible to infection during the early stages of involution and therefore decreasing the period of highest susceptibility while also improving the natural defense mechanisms is of great advantage over most therapies. Used alone, in various cytokine combinations, or in combination with other therapeutics, cytokines protect the mammary gland and cure existing infections and are particularly useful during cessation of lactation and early reinitiating of lactation.

Abstract: This invention pertains to immunogenic conjugates comprising a carbohydrate containing antigen or other antigen bound to or genetically fused with a cytokine, lymphokine, hormone or growth factor having immunomodulating activity, wherein the cytokine, lymphokine, hormone or growth factor is capable of modifying immunogenicity of the carbohydrate containing antigen. The cytokine or lymphokine can be an interleukin or an interferon. The immunogenic conjugate can be used in vaccine and co-vaccine formulations.

Abstract: A DNA sequence encoding a novel effector enzyme referred to as a cardiac adenylyl cyclase is described. The amino acid sequence of the cardiac adenylyl cyclase encoded by that DNA sequence is also described.

Abstract: The invention relates to a purified somatostatin receptor which is purified at least about 30,000-fold over the receptor which is membrane-bound. The invention also provides pharmaceutical compositions containing the receptor and antibodies to the receptor.

Abstract: The present invention relates to methods and compositions for the control and prevention of helmintic, arthropod ectoparasitic and acaridal infections, in warm-blooded animals, such as meat-producing animals, and poultry, by administering to said animals a therapeutically or prophylactically-effective amount of new agents designated LL-F28249.alpha., .beta., .gamma., .delta., .epsilon., .xi., .eta., .theta., .iota., .kappa., .lambda., .mu., .nu. and .omega., or mixtures thereof. The invention also relates to methods for the control of plant nematode infestations and other insecticidal activities. These novel agents are produced via a controlled conditioned microbiological fermentation using Streptomyces cyaneogriseus ssp. noncyanogenus, designated LL-F28249 and having deposit accession number NRRL 15773.

Abstract: The present invention relates to novel chimeric fibroblast growth factors (FGF) wherein the alanine at amino acid 3 and serine 5 of native human recombinant basic fibroblast growth factor are replaced with glutamic acid. The N-terminus sequence of the present chimeric FGFs identify homology with that of human acidic fibroblast growth factor. The mitogenic properties of the native human recombinant basic FGF are exhibited by the present chimeric FGFs, and they are efficiently expressed in E. coli at significantly greater yields that previously reported. Novel variants of this new glu.sup.3,5 basic fibroblast growth factor, such as those in which cysteine 78 and cysteine 96 are replaced, e.g., with serine or other amino acids, to produce stabilized versions of the glu.sup.3,5 basic FGF and eliminate disulfide scrambled forms, are also described.

Abstract: The present invention relates to somatotropin analogues with amino acid changes in the .alpha.-helix 3 regions of said somatotropins, changes in the .alpha.-helix 2 regions, combinations thereof plus combinations with other changes to the native amino acid sequence of somatotropins. The resulting analogues are stable for formulation in sustained release, formulations, while maintaining biological activity. Further, methods for conducting site-directed mutagenesis on DNA encoding proteins and/or polypeptides also are provided.

Abstract: The present invention relates to novel chimeric fibroblast growth factors (FGF) wherein the alanine at amino acid 3 and serine 5 of native human recombinant basic fibroblast growth factor are replaced with glutamic acid. The N-terminus sequence of the present chimeric FGFs identify homology with that of human acidic fibroblast growth factor. The mitogenic properties of the native human recombinant basic FGF are exhibited by the present chimeric FGFs, and they are efficiently expressed in E. coli at significantly greater yields that previously reported. Novel variants of this new glu.sup.3,5 basic fibroblast growth factor, such as those in which cysteine 78 and cysteine 96 are replaced, e.g., with serine or other amino acids, to produce stabilized versions of the glu.sup.3,5 basic FGF and eliminate disulfide scrambled forms, are also described.

Abstract: The present invention relates to novel fragments of basic fibroblast growth factor (bFGF). The mitogenic potency of one of these bFGF fragments, identified as HBF-2 is about 25-50 fold less than that of native bFGF but at least 10.sup.3 -10.sup.4 fold more active than that of previously reported synthetic fragments of bFGF. Therefore, the present invention provides the shortest fragment of bFGF that retains substantial biologic activity.

Abstract: The present invention relates to methods and compositions for the control and prevention of helmintic, arthropod ectoparasitic and acaridal infections, in warm-blooded animals, such as meat-producing animals, and poultry, by administering to said animals a therapeutically or prophylactically-effective amount of new agents designated LL-F28249.sub..alpha., .beta., .gamma., .delta., .epsilon., .xi., .eta., .theta., .tau., .kappa., .lambda., .mu., .nu., and .sub..omega., or mixtures thereof. The invention also relates to methods for the control of plant nematode infestations and other insecticidal activities. These novel agents are produced via a controlled conditioned microbiological fermentation using Streptomyces cyaneogriseus ssp. noncyanogenus, designated LL-F28249 and having deposit accession number NRRL 15773.

Abstract: This invention relates to new agents designated LL-F28249.alpha., LL-F28249.beta., LL-F28249.gamma., LL-F28249.delta., LL-F28249.epsilon., LL-F28249.zeta., LL-F28249.eta., LL-F28249.theta., LL-F28249.iota., LL-F28249.kappa., LL-F28249.lambda., LL-F28249.mu., LL-F28249.nu., and LL-F2924.omega., to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically and pharmacologically-acceptable salts thereof. The present invention includes within its scope the biologically pure culture which produces there agents, derived from a newly-discovered and previously uncultured microorganism, Streptomyces cyaneogriseus subsp. noncyanogenus, NRRL 15773.